Phencyclidine and glutamate agonist LY379268 stimulate dopamine D2High receptors: D2 basis for schizophrenia

Synapse
Philip Seeman, Hong-Chang Guan

Abstract

It has previously been reported that the glutamate ionotropic antagonist phencyclidine directly inhibits the release of prolactin in anterior pituitary cells in culture, suggesting that phencyclidine has a dopamine (DA)-like action on prolactin-releasing cells. It has also been reported that the glutamate metabotropic agonist LY379268 can stimulate the incorporation of [35S]GTP-gamma-S into DA D2Long receptors. The present study was done to examine whether such glutamatergic drugs had similar actions on the DA D2Short receptor. The present results show that phencyclidine, ketamine, and LY379268 also stimulated the incorporation of [35S]GTP-gamma-S into D2Short receptors. The proportion of D2Long and D2Short receptors existing in the high-affinity state were both markedly reduced by NaCl. While phencyclidine and LY379268 each stimulated the incorporation of GTP-gamma-S into D2Long and D2Short receptors, this stimulation was reduced by NaCl, with D2Short being much more sensitive than D2Long to the inhibition by NaCl. The binding of phencyclidine and LY379268 to D2High receptors in vivo was directly confirmed by the i.v. injection of phencyclidine and LY379268 in which 50% inhibited the binding of [3H]PHNO to the striatum ex vivo...Continue Reading

References

Oct 1, 1991·The American Journal of Psychiatry·D C Javitt, S R Zukin
Jul 1, 1989·Naunyn-Schmiedeberg's Archives of Pharmacology·S B Ross, D M Jackson
Mar 1, 1983·Journal of Analytical Toxicology·C B WalbergB N Schulze
Apr 1, 1984·Journal of Clinical Pharmacology·A J GianniniM C Giannini
Apr 1, 1982·The American Journal of Psychiatry·S CastellaniP M Adams
May 1, 1982·Journal of Toxicology. Clinical Toxicology·S CastellaniP M Adams
Nov 1, 1994·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·S O Ogren, M Goldstein
Aug 1, 1993·Synapse·P SeemanP S Anderson
Aug 1, 1995·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·A C LahtiC A Tamminga
Aug 29, 1996·European Journal of Pharmacology·G OlmosJ A García-Sevilla
Nov 5, 1997·Journal of Analytical Toxicology·G W KunsmanM L Smith
Mar 4, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J D Jentsch, R H Roth
Oct 26, 1999·Neuropharmacology·D D SchoeppJ A Monn
Jun 6, 2000·Brain Research. Molecular Brain Research·I S LiuP Seeman
Jun 14, 2000·European Journal of Pharmacology·F MurrayS Grimwood
Apr 17, 2001·American Journal of Therapeutics·A J GianniniM Condon
Sep 5, 2001·The American Journal of Psychiatry·D C Goff, J T Coyle
May 16, 2002·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·M PampilloM Lasaga
Dec 17, 2002·Journal of the History of the Neurosciences·Alan A Baumeister, Jennifer L Francis
Oct 23, 2004·Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine·Scot PoundsCrist N Filer
Mar 9, 2005·Proceedings of the National Academy of Sciences of the United States of America·Yosuke MorishimaShigetada Nakanishi
Apr 26, 2005·British Journal of Anaesthesia·D DalU Aypar
Oct 6, 2005·Synapse·Philip Seeman, Mercedes Lasaga
Jun 21, 2006·Synapse·Philip SeemanTomiki Sumiyoshi
Jul 20, 2006·Expert Opinion on Therapeutic Targets·Philip Seeman
Aug 2, 2006·The British Journal of Psychiatry : the Journal of Mental Science·E Pomarol-ClotetP C Fletcher
Apr 5, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Matthäus WilleitShitij Kapur
Apr 27, 2007·Psychopharmacology·Edward B PerryUNKNOWN Yale Ketamine Study Group

❮ Previous
Next ❯

Citations

Jul 8, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Reginald CannadyJoyce Besheer
Aug 21, 2013·Proceedings of the National Academy of Sciences of the United States of America·Ricardo Gil-da-CostaThomas D Albright
Dec 15, 2015·The International Journal of Neuropsychopharmacology·Alessandra Bonito-OlivaGilberto Fisone
Mar 1, 2015·Progress in Neuro-psychopharmacology & Biological Psychiatry·Meng-Lin LiWen-Jun Gao
Jul 21, 2010·Clinical Schizophrenia & Related Psychoses·Philip Seeman
Apr 10, 2013·Toxicology Letters·Chaoxuan Dong, K J S Anand
Jan 22, 2009·The International Journal of Neuropsychopharmacology·Bob OranjeRené S Kahn
Mar 31, 2009·Journal of Psychopharmacology·M J HuntS Kasicki
Feb 9, 2017·The Journal of Pharmacology and Experimental Therapeutics·Amanda M MapleRonald P Hammer
Jan 29, 2019·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Elisabeth PiccartMichael J Beckstead
Nov 4, 2017·Pharmacology & Therapeutics·Laura HondebrinkRemco H S Westerink

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.